Chemical formula: C₇₀H₉₂ClN₁₇O₁₄ Molecular mass: 1,431.038 g/mol PubChem compound: 25074887
Cetrorelix interacts in the following cases:
Cetrorelix has not been studied in patients with hepatic impairment and caution is therefore warranted.
Cetrorelix has not been studied in patients with renal impairment and caution is therefore warranted. Cetrorelix is contraindicated in patients with severe renal impairment.
Studies in animals have indicated that cetrorelix exerts a dose related influence on fertility, reproductive performance and pregnancy. No teratogenic effects occurred when the medicinal product was administered during the sensitive phase of gestation.
During or following ovarian stimulation an ovarian hyperstimulation syndrome can occur. This event must be considered as an intrinsic risk of the stimulation procedure with gonadotropins
An OHSS should be treated symptomatically, e.g. with rest, intravenous electrolytes/colloids and heparin therapy.
Luteal phase support should be given according to the reproductive medical centre’s practice.
Cases of allergic/pseudoallergic reactions, including life-threatening anaphylaxis with the first dose have been reported.
Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition. Treatment with cetrorelix is not advised in women with severe allergic conditions.
Cetrorelix is not intended to be used during pregnancy.
Cetrorelix is not intended to be used during lactation.
Studies in animals have indicated that cetrorelix exerts a dose related influence on fertility, reproductive performance and pregnancy. No teratogenic effects occurred when the medicinal product was administered during the sensitive phase of gestation.
Cetrorelix has no or negligible influence on the ability to drive and use machines.
The most commonly reported adverse reactions are local injection site reactions such as erythema, swelling and pruritus that are usually transient in nature and mild in intensity. In clinical trials, these effects were observed with a frequency of 9.4% following multiple injections of cetrorelix 0.25 mg.
Mild to moderate OHSS (WHO grade I or II) have been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Inversely, severe OHSS remains uncommon.
Uncommonly, cases of hypersensitivity reactions including pseudo-allergic/anaphylactoid reactions have been reported.
The adverse reactions reported below are classified according to frequency of occurrence as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Uncommon: Systemic allergic/pseudo-allergic reactions including life-threatening anaphylaxis.
Uncommon: Headache
Uncommon: Nausea
Common: Mild to moderate OHSS (WHO grade I or II) can occur which is an intrinsic risk of the stimulation procedure.
Uncommon: Severe OHSS (WHO grade III)
Common: Local reactions at the injection site (e.g. erythema, swelling and pruritus).
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
